Trials / Unknown
UnknownNCT04398940
A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer
A Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of TQ-B3139 in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 71 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, multi-center clinical trial to evaluate the safety and efficacy of TQ-B3139 capsules in patients with MET gene abnormal advanced non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ-B3139 | TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle. |
Timeline
- Start date
- 2020-08-11
- Primary completion
- 2022-01-31
- Completion
- 2022-10-31
- First posted
- 2020-05-22
- Last updated
- 2020-09-11
Locations
16 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04398940. Inclusion in this directory is not an endorsement.